Shigella 4V2
Alternative Names: Shigella Bioconjugate Vaccine - LimmaTech Biologics; Shigella-4V2Latest Information Update: 04 Oct 2024
At a glance
- Originator LimmaTech Biologics
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Shigella infections
Most Recent Events
- 04 Oct 2024 LimmaTech Biologics plans the phase II S4V03 trial for Shigella infections in October 2024 (NCT06615375)
- 29 Jul 2024 Preclinical trials in Shigella infections in Kenya (Parenteral)
- 29 Jul 2024 LimmaTech Biologics plans the phase-II S4V02 trial for Shigella infections (In infants, Prevention) in Kenya (Parenteral), (NCT06523231)